HomeCompareCIDM vs ABBV

CIDM vs ABBV: Dividend Comparison 2026

CIDM yields 679.12% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CIDM wins by $707863.80M in total portfolio value
10 years
CIDM
CIDM
● Live price
679.12%
Share price
$0.29
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$707863.90M
Annual income
$548,875,080,990.73
Full CIDM calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CIDM vs ABBV

📍 CIDM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCIDMABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CIDM + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CIDM pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CIDM
Annual income on $10K today (after 15% tax)
$57,724.96/yr
After 10yr DRIP, annual income (after tax)
$466,543,818,842.12/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, CIDM beats the other by $466,543,797,786.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CIDM + ABBV for your $10,000?

CIDM: 50%ABBV: 50%
100% ABBV50/50100% CIDM
Portfolio after 10yr
$353932.00M
Annual income
$274,437,552,881.24/yr
Blended yield
77.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CIDM
Analyst Ratings
5
Buy
Consensus: Buy
Altman Z
-9.1
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CIDM buys
0
ABBV buys
0
No recent congressional trades found for CIDM or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCIDMABBV
Forward yield679.12%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$707863.90M$102.3K
Annual income after 10y$548,875,080,990.73$24,771.77
Total dividends collected$694917.18M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CIDM vs ABBV ($10,000, DRIP)

YearCIDM PortfolioCIDM Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$78,612$67,911.71$11,550$430.00+$67.1KCIDM
2$583,054$498,939.85$13,472$627.96+$569.6KCIDM
3$4,082,356$3,458,487.45$15,906$926.08+$4.07MCIDM
4$26,999,144$22,631,023.69$19,071$1,382.55+$26.98MCIDM
5$168,770,360$139,881,275.75$23,302$2,095.81+$168.75MCIDM
6$997,772,294$817,188,008.40$29,150$3,237.93+$997.74MCIDM
7$5,582,779,743$4,515,163,388.99$37,536$5,121.41+$5582.74MCIDM
8$29,584,268,003$23,610,693,678.02$50,079$8,338.38+$29584.22MCIDM
9$148,587,685,132$116,932,518,368.72$69,753$14,065.80+$148587.62MCIDM
10$707,863,904,082$548,875,080,990.73$102,337$24,771.77+$707863.80MCIDM

CIDM vs ABBV: Complete Analysis 2026

CIDMStock

Cinedigm Corp., together with its subsidiaries, operates as distributor and aggregator of independent movie, television, and other short form content in the United States. The company operates through two segments, Cinema Equipment Business and Content and Entertainment Business. The company distributes its products for various brands, such as Hallmark, Televisa, ITV, Nelvana, ZDF, Konami, NFL, and NHL, as well as international and domestic content creators, movie producers, television producers, and other short form digital content producers. It also collaborates with producers, various brands, and other content owners to market, source, curate, and distribute content to targeted audiences through existing and emerging digital home entertainment platforms, including Apple, Amazon Prime, Netflix, Hulu, Xbox, Tubi, PlutoTV, Vudu, and cable/satellite video-on-demand; and distributes DVD and Blu-ray discs to wholesalers and retailers with sales coverage to approximately 48,000 retail storefronts, including Walmart, Target, Best Buy, and Amazon. In addition, the company operates various branded and curated over-the-top (OTT) entertainment channels and applications, including Docurama, CONtv, Dove Channel, Viewster Anime, Fandor, and Screambox; and Matchpoint, a software-as-a-service platform to automate the distribution of streaming content and OTT channels. Further, it provides monitoring, billing, collection, and verification support services to music and movie screens as well as directly to exhibitors and other third-party customers. The company was formerly known as Cinedigm Digital Cinema Corp. and changed its name to Cinedigm Corp. in September 2013. Cinedigm Corp. was incorporated in 2000 and is headquartered in New York, New York.

Full CIDM Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CIDM vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CIDM vs SCHDCIDM vs JEPICIDM vs OCIDM vs KOCIDM vs MAINCIDM vs JNJCIDM vs MRKCIDM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.